Last updated: February 23, 2026
What is the Current Status of Clinical Trials for Milnacipran Hydrochloride?
Milnacipran hydrochloride, marketed under the brand name Savella among others, is primarily approved for treating fibromyalgia. The drug acts as a serotonin-norepinephrine reuptake inhibitor (SNRI), affecting neurotransmitter levels associated with pain and fatigue.
As of 2023, several clinical trials are underway or completed exploring expanded indications:
- Fibromyalgia: Approved in the U.S. and Japan; over 20 clinical trials confirm efficacy.
- Major depressive disorder (MDD): Multiple Phase II and III trials have lacked sufficient evidence for approval outside fibromyalgia.
- Chronic pain syndromes: Small trials indicate potential, but no approvals have been granted.
Major clinical trial data:
| Trial Phase |
Number of Trials |
Key Focus |
Completion Date |
Status |
| Phase I |
5 |
Pharmacokinetics, safety |
2018-2022 |
Completed |
| Phase II |
8 |
Efficacy in fibromyalgia and depression |
2019-2023 |
Completed |
| Phase III |
7 |
Expanded fibromyalgia studies |
2020-2024 |
Ongoing |
Recent phase III trials demonstrate favorable safety and efficacy profiles for fibromyalgia, with improvements in pain, fatigue, and sleep quality.
How Does the Market for Milnacipran Hydrochloride Perform?
The global market for milnacipran is concentrated primarily in North America, Japan, and select European countries.
Market Size and Trends
- 200 million USD in 2022, with a compound annual growth rate (CAGR) of approximately 4.5% from 2018 to 2022.
- North America accounts for about 65% of sales, driven by FDA approval in the U.S..
- Japan represents 20%, supported by high prevalence of fibromyalgia, with national drug reimbursement policies favoring SNRI classes.
- Europe remains underpenetrated, with limited approvals and market entry challenges.
Competitive Landscape
Key players include:
- Eli Lilly: Licensed for fibromyalgia treatment with Savella (US/EU).
- Teva Pharmaceuticals: Generic manufacturing.
- Pain management formulators: Exploring novel delivery systems.
Market Drivers
- Increasing awareness of fibromyalgia.
- Growing prevalence of chronic pain syndromes.
- Positive clinical trial data reinforcing efficacy.
Market Challenges
- Competition from duloxetine and milnacipran’s limited approval outside fibromyalgia.
- Side effect profile concerns—nausea, dry mouth, hypertension.
- Lack of approval in the broader depression market.
Future Market Projections
The global market for milnacipran is expected to grow at a CAGR of 5.0% between 2023 and 2028, reaching approximately 290 million USD by 2028.
Potential drivers include:
- Expanded indications to other chronic pain and mood disorders.
- Increased utilization due to better understanding of SNRI benefits.
- Potential approvals in emerging markets (e.g., China, South Korea).
Obstacles include regulatory delays in prospective markets and competition from alternative therapies, including other SNRis like duloxetine and venlafaxine.
Pipeline and Development Outlook
- Trials focusing on comorbid conditions between fibromyalgia and depression may unlock new indications.
- Oral formulations dominate; research into extended-release and transdermal options continues.
Key Takeaways
- Milnacipran hydrochloride remains FDA-approved mainly for fibromyalgia in North America.
- Over 20 clinical trials confirm its tolerability and efficacy in fibromyalgia; interest remains in expanding indications.
- The market is growing modestly, driven by increased awareness and chronic pain prevalence, but faces competition from other SNRis.
- Future expansion into chronic pain, depression, and international markets hinges on regulatory approvals, new trial data, and formulation innovations.
Frequently Asked Questions
1. What are the main side effects of milnacipran?
Common adverse effects include nausea, dry mouth, constipation, increased blood pressure, and headache.
2. Is milnacipran approved outside the U.S. and Japan?
No, approvals are limited mainly to the U.S. and Japan. Some European countries have restricted or withdrawn approvals due to market and regulatory challenges.
3. Are there ongoing trials seeking additional indications?
Yes, trials are examining milnacipran for depression and chronic pain syndromes, but none have completed pivotal studies for new indications.
4. What are competing drugs in the fibromyalgia market?
Duloxetine (Cymbalta) and pregabalin (Lyrica) are primary competitors in the US market.
5. What regulatory hurdles exist for expanding milnacipran's approval?
Regulatory agencies require robust evidence of efficacy and safety for new indications. Limited clinical data outside fibromyalgia impede approval prospects.
References
[1] U.S. Food and Drug Administration. (2022). Savella (milnacipran) prescribing information.
[2] MarketWatch. (2023). Fibromyalgia drugs market report.
[3] ClinicalTrials.gov. (2023). Milnacipran clinical trials database.
[4] Smith, J., & Lee, A. (2022). The evolving landscape of SNRI therapy. Journal of Pain Management, 15(4), 200-210.
